Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177629 | 1.00 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2TSHRMGAMGAA | |
| SCHEMBL27840950 | 0.82 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL4986801 | 0.80 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL41033 | 0.80 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13278346 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2TSHRMGAMGAA | |
| Hydrochloric Acid SCHEMBL2533779 | 0.78 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL10009158 | 0.77 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL16160125 | 0.77 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TSHRTGFBR1EGLN1 | |
| SCHEMBL7914785 | 0.77 | TSHR (0.31) | TSHR | |
| SCHEMBL10009153 | 0.77 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783511-B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | ALDH1A1 350/4885SMN1; SMN2 2661/4885TSHR 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.